Search research articles
Contact Us
Filters
Showing results (71-80 of 132) with videos related to
Page
of 14
Sort By:
Frontiers in Pharmacology
|
October 16, 2019
Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate
Madelé van Dyk, Asha J Kapetas, Ashley M Hopkins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 13, 2008
Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro
Shu-Ying Chang, Wenying Li, Sarah C Traeger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 22, 2005
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions
Brian W Ogilvie, Donglu Zhang, Wenying Li, et al.
Clinical Pharmacology and Therapeutics
|
October 4, 2021
Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions
Emi Kimoto, Chester Costales, Mark A West, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 1, 2013
Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions
Yoshiyuki Shirasaka, Shu-Ying Chang, Mary F Grubb, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C
Timothy Eley, Bing He, Shu-Pang Huang, et al.
Bioanalysis
|
May 12, 2018
A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III
Amanda King-Ahmad, Sara Clemens, Ragu Ramanathan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 7, 2013
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats
Donglu Zhang, Charles E Frost, Kan He, et al.
The AAPS Journal
|
September 1, 2021
Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin
Asha J Kapetas, Ahmad Y Abuhelwa, Michael J Sorich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 16, 2003
Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450
Magang Shou, Ryan Norcross, Grit Sandig, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 132) with videos related to
Sort By:
Page
of 14
Frontiers in Pharmacology
|
October 16, 2019
Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate
Madelé van Dyk, Asha J Kapetas, Ashley M Hopkins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 13, 2008
Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro
Shu-Ying Chang, Wenying Li, Sarah C Traeger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 22, 2005
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions
Brian W Ogilvie, Donglu Zhang, Wenying Li, et al.
Clinical Pharmacology and Therapeutics
|
October 4, 2021
Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions
Emi Kimoto, Chester Costales, Mark A West, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 1, 2013
Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions
Yoshiyuki Shirasaka, Shu-Ying Chang, Mary F Grubb, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C
Timothy Eley, Bing He, Shu-Pang Huang, et al.
Bioanalysis
|
May 12, 2018
A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III
Amanda King-Ahmad, Sara Clemens, Ragu Ramanathan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 7, 2013
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats
Donglu Zhang, Charles E Frost, Kan He, et al.
The AAPS Journal
|
September 1, 2021
Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin
Asha J Kapetas, Ahmad Y Abuhelwa, Michael J Sorich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 16, 2003
Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450
Magang Shou, Ryan Norcross, Grit Sandig, et al.
Page
of 14